Nautilus will host a conference call to discuss the first quarter 2025 financial results, business developments and outlook before market open on Tuesday, April 29, 2025, at 5:30 AM Pacific Time / ...

Few of Elon Musk’s companies would have been possible without the energy density and stability of lithium-ion batteries. In ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment ...

The company, which has been targeted by Washington, saw US revenue jump 28 per cent in the first quarter, compared with 21 ...

Enhancing wheat plants' sugar signaling ability could deliver increased yields of up to 12%, according to researchers from ...

AML patients in the trial who were treated with SENTI-202 experienced complete remission after not responding to prior ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

HudsonAlpha Institute for Biotechnology is looking for participants to take part in a new pilot study to see how genetics and ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq ...